An observational study of patients receiving T-DXd for treatment of HER2+, and HER2-low unresectable and/or metastatic breast cancer - DB RESPOND

Study identifier:D9673R00025

ClinicalTrials.gov identifier:NCT05592483

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer

Medical condition

Breast Cancer

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

28

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 07 Jul 2023
Primary Completion Date: 29 May 2024
Study Completion Date: 29 May 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria